Form 8-K - Current report:
SEC Accession No. 0001193125-25-005020
Filing Date
2025-01-13
Accepted
2025-01-13 08:18:03
Documents
18
Period of Report
2025-01-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d915237d8k.htm   iXBRL 8-K 26321
2 EX-99.1 d915237dex991.htm EX-99.1 15243
3 EX-99.2 d915237dex992.htm EX-99.2 8689
7 GRAPHIC g915237ex99_2s1g1.jpg GRAPHIC 175082
8 GRAPHIC g915237ex99_2s2g1.jpg GRAPHIC 78539
9 GRAPHIC g915237ex99_2s3g1.jpg GRAPHIC 68951
  Complete submission text file 0001193125-25-005020.txt   631257

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA krro-20250113.xsd EX-101.SCH 2841
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE krro-20250113_lab.xml EX-101.LAB 18757
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krro-20250113_pre.xml EX-101.PRE 11704
21 EXTRACTED XBRL INSTANCE DOCUMENT d915237d8k_htm.xml XML 3804
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 25524942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)